ATF3-Binding Peptides for Inflammatory Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective inhibitors for the ATF3 protein, which is involved in inflammatory, metabolic, and autoimmune diseases, and there is a need for substances that can regulate its expression and function to inhibit inflammatory responses.
Innovation Solution
Development of peptides, such as those represented by SEQ ID NOS: 1 to 4, and their fusion peptides with cell permeability, which bind to the ATF3 protein, thereby inhibiting its signaling pathway and reducing inflammatory cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used, then current therapeutic options are available, but effective inhibitors for ATF3 protein are not developed
Solution Approach 1:
The invention segments the problem by developing specific peptide inhibitors (SEQ ID NOS: 1-4) that target different aspects of ATF3 function, rather than relying on a single conventional treatment approach. This segmentation allows for specialized inhibition of ATF3-mediated inflammatory pathways while maintaining other physiological functions.
Solution Approach 2:
The patent introduces peptide molecules as intermediary substances that mediate between the ATF3 protein and its target genes. These peptides bind to ATF3 and prevent it from activating inflammatory gene transcription, serving as a molecular intermediary that blocks the harmful signaling pathway without directly affecting the target genes.
2Object-affected harmful factors
If ATF3 expression is regulated to inhibit inflammatory response, then inflammatory diseases can be treated, but no effective substances have been developed to date
Solution Approach 1:
The invention employs short peptides (12-15 amino acids) as disposable inhibitory molecules that can be easily synthesized and administered. These short-lived peptide inhibitors provide temporary but effective blockade of ATF3 function, allowing for flexible dosing and reducing accumulation of side effects.
Solution Approach 2:
The patent utilizes parameter changes in peptide structure (different amino acid sequences in SEQ ID NOS: 1-4) to optimize binding affinity and selectivity for ATF3. By modifying peptide parameters such as sequence, length, and composition, the invention achieves effective inhibition with manageable production requirements.
3Object-generated harmful factors
If peptides bind to ATF3 to inhibit signaling pathway, then inflammatory cytokine production is reduced, but cell permeability must be ensured for effective delivery
Solution Approach 1:
The invention creates composite peptide structures that combine ATF3-binding domains with cell-permeable sequences. These composite peptides integrate multiple functions: specific binding to ATF3, efficient cellular uptake, and effective intracellular inhibition, resolving the contradiction between targeting specificity and delivery efficiency.
Solution Approach 2:
The peptides serve as intermediaries that facilitate the transfer of inhibitory function from the extracellular environment into the cell nucleus where ATF3 acts. By mediating this transport and binding process, the peptides overcome the permeability barrier while maintaining their inhibitory function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively reduce the production of inflammatory cytokines and show therapeutic potential in treating inflammatory, metabolic, and autoimmune diseases by binding to ATF3, as demonstrated in animal models of non-alcoholic steatohepatitis and inflammatory bowel disease.
Implementation Method 1
a peptide having ATF3-binding ability represented by one amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 4
Data Source
AI summary
The present invention pertains to: a peptide having ATF3-binding ability and represented by any one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 4; a fused peptide in which a cell-permeable peptide is bound to the peptide having ATF3-binding ability; and a use of the peptides for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. According to the present invention, a novel peptide having the ability to bind to ATF3, which is a protein serving as a biomarker and an important factor in the occurrence of various inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases, is provided to thereby regulate the intracellular concentration of ATF3, and can thus be used for the treatment of inflammatory diseases, metabolic diseases, autoimmune diseases and/or fibrotic diseases. Moreover, the disease treatment effect can be enhanced by further fusing a peptide having intracellular permeability and an inflammation inhibitory function to the peptide.